Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 13/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | PDE2A | O00408 | 1/20 | 0.40 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2993813 | 0.81 | HSD11B1 (0.52) | HSD11B1MAOAPDE2APDE10ANPC1 | |
| SCHEMBL2994768 | 0.81 | HSD11B1 (0.55) | HSD11B1MAOANPC1ALDH1A1LMNA | |
| SCHEMBL2985478 | 0.79 | HSD11B1 (0.56) | HSD11B1NPC1ALDH1A1LMNARAB9A | |
| SCHEMBL2995278 | 0.79 | HSD11B1 (0.52) | HSD11B1MAOAPDE2APDE10ANPC1 | |
| SCHEMBL2992850 | 0.77 | HSD11B1 (0.56) | HSD11B1NPC1ALDH1A1LMNARAB9A | |
| SCHEMBL7980912 | 0.76 | HSD11B1 (0.67) | HSD11B1NPC1ALDH1A1LMNARAB9A | |
| SCHEMBL18905854 | 0.75 | HSD11B1 (0.71) | HSD11B1NPC1ALDH1A1LMNARAB9A | |
| SCHEMBL2995389 | 0.74 | SMO (0.35) | HSD11B1SMN1; SMN2 | |
| SCHEMBL2983487 | 0.73 | HSD11B1 (0.67) | HSD11B1NPC1ALDH1A1LMNARAB9A | |
| SCHEMBL2983476 | 0.72 | HSD11B1 (0.61) | HSD11B1NPC1ALDH1A1LMNARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7776897-B2 | such as 3-[1-(5-chloro-2-thienyl)cyclopenty]-5,6,7,8,9,10-hexahydro [1,2,4]triazolo[4,3-a]azocine, having a strong 11 beta -hydroxysteroid dehydrogenase type 1inhibitory activity and exhibiting an excellent blood-glucose level-lowering action, used for the therapy of diabetes and insulin resistance | ASTELLAS PHARMA INC. (JP) | 2010-08-17 | — | — | US | disclosed |
| US-20070259854-A1 | Triazole Derivative or Salt Thereof | ASTELLAS PHARMA INC. (JP) | 2007-11-08 | — | — | US | disclosed |
| EP-1790641-A1 | TRIAZOLE DERIVATIVE OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2007-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259854-A1 | Triazole Derivative or Salt Thereof | HSD11B1, HSD11B2, HSD3B1 | HSD11B1 1/4885MAOA 3825/4885PDE2A 934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.